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Abstract
Introduction: The opening of research data is emerging thanks to the increasing possibilities of digital technology. The opening of clinical trial (CT) 
data is a part of this process, expected to have positive scientific, ethical, health, and economic impacts thus contributing to research integrity. The 
January 2016 proposal by the International Council of Medical Journal Editors triggered ample discussion about CT data sharing and reconfirmed 
the need for an ongoing assessment of its dynamics. The IMProving Access to Clinical Trials data (IMPACT) Observatory aims to play such a role, and 
assess the data sharing culture, policies, and practices of key players, the impact of their interventions on CTs, and contribute to a transformation of 
research. The objective of this paper is to present the IMPACT Observatory as well as share some of its preliminary findings. 
Materials and methods: Methods include a scoping study of research, surveys, interviews, and an environmental scan of research data repositories. 
Results: Our preliminary findings indicate that although opening of CT data has not yet been achieved, its evolution is encouraging. Initiatives by 
key players contribute to increasing of CT data sharing, and many barriers are shrinking or disappearing. 
Conclusions: The major barrier is the lack of data sharing standards, from preparing data for public sharing to its curatorship, findability and access. 
However, experiences accumulated by sharing CT data according to “upon request” or “open” mechanisms could inform the development of such 
standards. The Vivli, CORBEL-ECRIN and Open Trials projects are currently working in this direction.
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Introduction
It has become increasingly clear that the reliable 
evidence needed for decision making in health as 
in other fields has to be based on all existing 
knowledge and that re-analysis of raw data of re-
search performed is the way to get it. 
The opening of research data is a relatively new 
field enabled by increasing possibilities of digital 
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technology (1). The opening of clinical trial (CT) 
data is part of the overall tendency to achieve 
open science. The increased sharing and reuse of 
data is expected to lead to positive scientific, ethi-
cal, health, and economic outcomes promising to 
improve the quality of research and speed up 
knowledge creation, thus contributing to research 
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integrity (2). Through the opening of CT data, we 
could avoid unnecessary research, provide more 
reliable evidence for decision-making, reduce re-
search waste, enable entrepreneurship, and facili-
tate innovation. This is a complex process largely 
influenced by culture, perceptions, and policies of 
numerous key players. The January 2016 proposal 
by the International Committee of Medical Journal 
Editors (ICMJE) to request the sharing of raw data 
from published CTs is an example of a recent initi-
ative aiming to increase the reusability of CT data 
(3) and it came as no surprise that it triggered a big 
interest considering the impact of their 2004 trial 
registration statement (4).
In order to achieve broader sharing and eventually 
opening of CT data, numerous barriers and obsta-
cles must be overcome. The effort to find a new 
balance of CT data sharing has intensified, and 
there currently exist a number of data sharing ini-
tiatives led by various players. This process would 
benefit from the observation and assessment of its 
dynamics and an observatory or natural experi-
ment is proposed as a methodology of choice to 
inform and contribute to its progress. 
It is widely accepted that the level of reliability of 
evidence needed for evidence-informed decision-
making increases from in vitro to interventional 
studies, as is illustrated by the famous evidence 
pyramid presented in Figure 1. 
The plethora of research studies that mostly build 
on each other from basic via observational to in-
terventional studies produce findings that need to 
be critically verified. The critical appraisal of rand-
omized controlled trials (RCT), which are consid-
ered by many to be the gold standard, was first in-
troduced through systematic reviews (5). The evo-
lution of literature review is important for under-
standing data sharing. It evolved from the simple 
literature review all the way to the Cochrane over-
view of systematic reviews, with critical reviews of 
literature, overviews, systematic reviews and 
Cochrane systematic reviews in between.
Although Cochrane systematic reviews represent 
a relatively small portion of all systematic reviews, 
Cochrane contributed enormously to establishing 
standardized methodology and thus increased 
their quality. Along with the recognition of the 
benefit of a cumulative approach to the assess-
ment of evidence, this enabled systematic reviews 
to become a key element to inform decision mak-
ing. The interest in and importance of systematic 
reviews can be illustrated by the existence of reg-
istries of systematic reviews, such as PROSPERO (6).
It is important to emphasize that the systematic 
review paradigm has been changing as we are 
adding another level of critical appraisal and 
knowledge creation, the analysis of raw data, actu-
ally of the individual participant data (IPD). Meta-
analysis of IPD may be included in a systematic re-
view. In such IPD meta-analyses, published litera-
ture is used as one of many sources of information, 
often as a starting point for identifying studies in a 
given field. Additional studies and data are identi-
fied through other sources such as trial registries 
and research data repositories (repositories). Such 
analysis goes beyond synthesizing the reported 
data - it reanalyzes the IPDs, published or not. As 
illustrated in Figure 1, the reanalysis of IPDs will 
speed up knowledge creation. 
Figure 1. Evidence pyramid.
The hierarchy of evidence and the role of the individual par-
ticipant data (IPD) meta-analysis in knowledge creation is pre-
sented. The reliability of evidence needed for the evidence in-
formed decision making in health increases as we move up the 
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The IMProving Access to Clinical Trial data (IM-
PACT) Observatory is monitoring various current 
initiatives aimed at making data available for fur-
ther research, in order to assess changes in the 
paradigm of the CT enterprise (7).
If data are to be re-used and re-analysed, it is es-
sential to know how to share them, where one can 
deposit them, and in which format, how to find 
them, and how one can access data for any type of 
re-use. While some key players engage in sharing 
and re-analyzing CT data, others play the catalyst-
type role of triggering the process. The loss of data 
from studies, no matter how small, is of major con-
cern, especially with regards to research integrity 
and research waste. The first and most critical step 
of data sharing is their preservation at the source. 
The overall objective of the IMPACT Observatory is 
to identify the impact on CTs of data sharing inter-
ventions and practices by key players (funders, 
regulators, journal editors, pharmaceutical indus-
try, researchers, institutions, and consumers), to 
identify barriers and facilitators, inform the pro-
cess, and to indicate trends and potential solu-
tions. Once established, the IMPACT Observatory 
would function as a two-way street: a) it would 
collect, assess, analyze and host the information 
gathered and shared by the IMPACT Observatory 
network regarding changes in data sharing poli-
cies, practice and standards; and b) it would make 
the information available to those that aim to 
make changes to policies and practices or to de-
velop new standards.
The objective of this paper is to present the IM-
PACT Observatory as a tool to assess changes in CT 
data sharing, as well as to present some of its pre-
liminary findings regarding the dynamics of CT 
data sharing and ways data are shared in order to 
be reanalyzed. We also propose potential mecha-
nisms that could enable the useful opening of CT 
data.
Materials and methods
The IMPACT Observatory is an international study, 
hosted by the Department for Research in Bio-
medicine and Health of the University of Split 
School of Medicine. It started in October 2014, 
evolving from the IMPACT Initiative (7). It was ap-
proved by the Ethics Committee of the University 
of Split, School of Medicine. Observatories or natu-
ral experiments are epidemiological studies that 
assess the impact of one or more interventions 
that are not controlled by the observatory 
researcher(s), in order to inform the process and 
indicate trends (8,9). While an observatory might 
follow the impact of interventions by one player, 
the IMPACT Observatory is assessing the impact of 
data sharing interventions by multiple players.
In our study we use the term “data sharing” in its 
broad sense, which includes the sharing and reuse 
of data. The term “data” is also used in a broad 
term, denoting the cleaned, anonymized IPDs 
along with all other documentation generated 
during the lifecycle of a clinical trial that is needed 
to reuse data. This includes published and unpub-
lished documents, such as trial protocols, data 
management and statistical plans, informed con-
sent and patient information sheets, regulatory 
and ethical documents, and clinical study reports. 
We started setting up the IMPACT Observatory by 
building a network and choosing the methodolo-
gy. A unique methodological aspect of the IM-
PACT Observatory is the development of a multi-
purpose network with a flexible interface between 
the network and the team, enabling people to 
move from one to another according their interest 
and level of engagement. As presented in Table 1, 
we used a combination of quantitative and quali-
tative research methods to assess the culture, per-
ceptions and practice of key players regarding CT 
data sharing and its transition. This includes a 
scoping study, i.e. mapping of the existing evi-
dence, surveys, interviews, and an environmental 
scan of research data repositories that host CT 
data (9). 
The scoping study included an Internet and litera-
ture search. For the latter, we performed a search 
in Medline, selected the literature that met our cri-
teria, and extracted pre-defined information into 
an excel file to analyze it. Surveys were used to 
gather quantitative and qualitative information 
from key players. The questionnaire contains ques-
tions about the practice and perceptions of the 
participants with regards to data sharing and re-
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use. So far, we have performed a web-based sur-
vey using SurveyMonkey (SurveyMonkey Inc., Palo 
Alto, USA) of journal editors and clinician trialists, 
the results of which are currently being analyzed. 
Semi-structured in-depth interviews were per-
formed with a convenient sample of key players. 
Once the players agreed to be interviewed, a short 
pre-interview questionnaire was sent to them in 
order to gather quantitative information (e.g. “Did 
you perform a trial?”, “How many?”; “Did you regis-
Task What and who Why/Rationale
Develop and maintain* 
the IMPACT Observatory 
network
Contact, discuss, and engage 
interested people
Network members provide and/or use the information, join 
the team for specific tasks, and support it in other ways
Scoping study/baseline Search, select, and analyze the 
literature and websites
Set a baseline at 2000; assess the clinical trial data sharing 
situation at baseline
Scoping study/clinical 
trial data sharing since 
2000
Search, select, and analyze literature, 
websites, and contacts
Assess data sharing evolution over time until June 2016 and 
then update regularly*
Survey of key players 
2015 / 2016
SurveyMonkey used to survey 
clinician trialists, editors, consumers
Identify culture, positions and practices regarding data 
sharing and reuse; compare
Survey of key players in 
2017- onwards*
Repeat in two years and expand to 
other players
Assess changes over time
Interviews of key 
players 2015 / 2016
Semi-structured interviews, 
convenient sample
Identify policies, positions and practices regarding data 
sharing and reuse of key players
Interviews 2017 - 
onwards*
Follow-up Assess changes over time
Environmental scan 
of research data 
repositories
Identify and analyze repositories that 
host clinical trial data
Analyze repository features regarding sharing and reusability 
of data
Data sharing initiatives Internet; contacts; literature Monitor initiatives and assess their impact on sharing and 
reuse of data
Promote the IMPACT 
Observatory 
Communication and dissemination Promote the IMPACT Observatory as a long-term tool. Ensure 
input and use of the IMPACT Observatory. Build sustainability 
of the IMPACT Observatory
Inform and indicate 
trends
Knowledge translation through 
publications, conferences, website
Inform so that key players can use the IMPACT Observatory in 
their policy making, in development of data sharing methods 
and standards, and to contribute to the sustainability of the 
Observatory
Build sustainability of 
the IMPACT Observatory
Various forms of promotion of the 
IMPACT Observatory; applications for 
sponsoring and funding
IMPACT Observatory is established as a long-term tool to 
inform the process of data sharing and its impact on clinical 
trials
*These tasks are anticipated in case the IMPACT Observatory continues beyond the initial fellowship.
Table 1. IMPACT Observatory – Methodology
ter the trial?”; “What did you do with the data?”) 
and help structure the interview questions. Envi-
ronmental scans of repositories that host clinical 
trial data are performed by identifying relevant re-
positories on the internet, especially through visit-
ing registries of repositories, then extracting the 
pre-defined information from registry and reposi-
tory websites into an excel file, and complement 
the information by communicating with the re-
positories managers. 
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Results
Results regarding establishing the IMPACT 
Observatory 
The IMPACT Observatory officially started in Octo-
ber 2014 as an international study of the IMPACT 
Initiative. We incorporated and continued the en-
vironmental scan of repositories, which has been 
performed by one of the authors since 2012 (7).
Having defined CTs as our area of research, we 
started building the network and established a 
core team. We identified key players that influence 
CT data sharing; these are journal editors, publish-
ers, clinicians, trialists/CT researchers, academia, 
funders, regulators, industry, consumers, the me-
dia, and repositories. Furthermore, we chose the 
methodology and started implementing it. During 
this one and a half year period, we presented the 
IMPACT observatory at several conferences to in-
form the scientific community and receive their 
feedback. As of summer 2016, the scoping study, 
analyses of two completed surveys and interviews 
are still ongoing as is data collection and the anal-
ysis of the environmental scan. Here we shall pre-
sent some of our preliminary findings.
Preliminary findings of the IMPACT 
Observatory
Scoping study findings
In our scoping study, the baseline was set to 2000 
when the basic prerequisites, i.e. foundations for 
data sharing, were present. These included: the 
understanding of the need for higher transparen-
cy in clinical trials and for the sharing of raw data, 
the call for and establishment of initial CT regis-
tries, a defined basic methodology for systematic 
reviews, the launch of the Cochrane Collaboration 
(since 2015 called Cochrane), and the existence of 
IPD meta-analyses (10-12).
In the period following the year 2000, the opening 
of CT data experienced more rapid growth. The 
major trigger took place in 2004 with the historical 
New York City against the GlaxoSmithKline Phar-
maceutical Company (GSK) trial followed by the IC-
MJE and the Ottawa Statements, that led to the de-
velopment of International standards for trial regis-
tration by the World Health Organization (WHO) 
(4,13-15). It should be emphasized that ICMJE, joined 
by other journal editors, has repeatedly played an 
essential role in advancing CT data sharing.
Barriers and gaps
As shown in Figure 2, numerous barriers and gaps 
prevent the opening of data and the related tran-
sition of CTs. Between 2013, when this schematic 
was created during the process of planning the 
IMPACT Observatory, and 2016, most of these bar-
riers have diminished or were even overcome due 
to the interventions of various players, one or sev-
eral at a time. For example, the fear of prepublica-
tions is dealt with by journal editors, while citabili-
ty is addressed by assigning a digital object identi-
fier (DOI) or some other unique identifier (3). Con-
cerns over the privacy of research participants is 
still present albeit it is a perception rather than a 
real barrier since effective methodologies for an-
onymization have been developed (16).
The concept of intellectual property (IP) remains a 
barrier but this barrier is shrinking. Furthermore, 
even in this field burdened with IP concerns and 
protections, culture and perceptions are changing 
and various mechanisms of data sharing for reuse 
are being developed, some of which are present-
ed in this paper. Finally, the lack of international 
standards of data sharing and of research data re-
positories are still major barriers that need to be 
addressed. 
Data sharing initiatives
Various key players are taking initiatives, holding 
discussions, producing statements and declaring 
policies regarding research data sharing (17–19). 
Many have contributed substantially to its in-
crease, including the ICMJE, Ottawa statement, 
WHO, Cochrane, Declaration of Helsinki, the RE-
WARD (REduce research Waste And Reward Dili-
gence) Campaign, the Institute of Medicine report 
(IOM), and the AllTrials initiative (14,20-25). It is im-
portant to note that regulators play an important 
role, as can be seen from the European Medicine 
Agency (EMA) 2014 policy on data sharing and its 
consequent actions sharing the clinical study re-
ports (CSR) (26,27).
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Figure 2: Barriers preventing the public disclosure of clinical trial data.
The figure presents the barriers that prevent the opening of clinical trial data identified in 2013 and a dynamics of their change. 
They are diminishing due to initiatives by key players. The lighter part of each barrier illustrates the tendency of shrinking or even 
overcome. *The Culture barrier includes a balance of opportunities vs fear; lack of appreciation of the research opportunities that 
data sharing provides, fear of the human and financial resources needed; lack of recognition of sharing as a good practice; lack of 
incentives for academics; †Data barrier includes the issues of data accuracy and quality, and the lack of standards of preparing data 
for sharing; ‡Repositories as a barrier: lack of domain repository and the lack of data sharing standards via repositories: upload/host/
maintenance/ access.  
While citability of data is solved by assigning a per-
sistent identifier, finding of available data is still a 
challenge. The ongoing bioCADDIE project of the 
BD2K aims to develop an index of all available re-
search data, similar to what PubMed did for litera-
ture (28). 
There are additional initiatives aiming to contrib-
ute to this issue, such as the EU-funded project 
CORBEL (Coordinated Research Infrastructures 
Building Enduring Life-Science Services, www.cor-
bel-project.eu). Corbel plans to establish a collabo-
rative platform for harmonized user access to bio-
logical and medical research technologies, biolog-
ical samples and data services required by cutting-
edge biomedical research. ECRIN (the European 
Clinical Research Infrastructure Network) leads the 
CORBEL task groups focused on developing pro-
cedures and tools to provide the scientific commu-
nity with access, upon request, to the IPDs from 
previous clinical trials for various forms of re-use. 
Another example is the Open Trials which aims to 
locate, match, and share all publicly accessible 
data and documents, on all trials conducted, on all 
medicines and other treatments, globally (29). 
There is also “Vivli”, a recently launched data-shar-
ing platform aimed at sharing clinical trial data, 
developing and promoting standards, and im-
proving trial discoverability. It will be designed by 
linking existing data-sharing platforms and com-
munities and plans to include trials funded and 
conducted by academia, government, industry, 
and nongovernmental organizations (30). The 
main added value of “Vivli” will be its contribution 
to the creation of standards that would enable the 
re-analysis of CT data across different platforms 
and including all relevant players in the process.
Ongoing data sharing
Currently there are numerous mechanisms of data 
sharing. We have identified multiple formulas of 
data sharing that vary according to the type of ac-
cess (from “upon request” to “open”), the data pro-
ducer and user (trialist, systematic reviewer, aca-
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researcher to regulator), the CT area (any CTs; dis-
ease specific, e.g. malignant melanoma; groups of 
disease, e.g. cancer, mental health; population 
specific). 
We identified several “upon request” styles of 
sharing and re-using of CT data:
•	 Researcher to researcher requests such as most 
Cochrane IPD meta-analyses. Direct, research-
er-to-researcher sharing often includes an offer 
to the initial data producer to become co-au-
thor of the systematic review. 
•	 Researcher-to-regulator (EMA, FDA) request, in-
cluding requests for clinical study report (CSR) 
which contain rich information including ag-
gregate data but usually not the IPDs (31,32).
•	 Direct requests to a pharmaceutical industry, 
which often have strings attached, and are con-
ditioned by an agreement that usually includes 
confidentiality, secrecy, and non-sharing (32).
•	 Requests via an intermediary that organizes the 
processing of the application, while data own-
ers still control the access to data. 
These “upon request” data sharing styles include 
sharing of raw data and/or sharing of comprehen-
sive reports such as CSRs and other information. 
They are increasingly performed in an organized 
way as a project or initiative. They all have some 
form of registration, application/request, and ap-
proval process followed by a signed agreement. 
Three data sharing projects facilitated by interme-
diaries are described below. The YODA project is a 
partnership between Yale University and three 
companies (33). The Clinical Study Data request 
(CSDR) is a project in which 13 companies agreed 
to share their participant-level anonymized CT 
data (34). The Welcome Trust has been coordinat-
ing the application process, including the peer re-
view of data request applications. Project Data 
Sphere is focused on data from phase III cancer tri-
als. It is an independent, not-for-profit initiative of 
the CEO Roundtable on Cancer Life Sciences Con-
sortium formed in 2011 by more than 30 pharma-
ceutical companies and other organizations. It 
aims to share data from historic academic and in-
dustry phase III cancer CTs (35). Figure 3 illustrates 
the partnerships of pharmaceutical companies in 
these projects. It is interesting to note that several 
companies share their data through more than 
one project, while Johnson & Johnson made their 
data available through all three projects. 
Open data and research data repositories
Open science needs open data. It has been in-
creasingly understood that the first step in data 
sharing and reuse is the preservation of data at the 
source and it must be done in a systematic way. 
Unfortunately, this is still not the case as can be 
seen in the preliminary results of our survey con-
ducted with corresponding authors of trials pub-
lished in 2013. Less than 50% of those that re-
sponded had saved their trial data in the organiza-
tional database and more than 50% had kept the 
data on their local computers. However, we no-
ticed a recent trend towards the creation of reposi-
Figure 3. Projects facilitating access to study sponsors’ IPDs in 
the upon request style.
The 25 companies presented partner with Datasphere, Yoda, 
and ClinicalStudyDataRequest in order to share clinical trial 
data in the upon request style, as of June 2016. Nineteen com-
panies partner in the Project Datasphere to share and reuse 
data from academic and industry phase III cancer studies. Clini-
caStudyDataRequest facilitates the access to clinical trial data 
from 13 companies, and Yoda from 3. Several companies share 
their data through more than one project, while Johnson & 
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tories by academia in order to preserve data gen-
erated by their researchers. Ideally, such institu-
tional repositories would forward data to broader 
national or international repositories such as Fig-
share and Dryad (36,37). They would also create a 
federation of repositories to enable interoperabili-
ty and reuse of data. 
Research data repositories (repositories) are elec-
tronic databases that host research data and facili-
tate their re-use. The following types of reposito-
ries are relevant for this discussion:
1. CT registries that host essential elements of CT 
protocols, some of them including summary re-
sults. They can be accessed via the WHO portal; 
(38)
2. registries of systematic reviews (such as Co-
chrane and PROSPERO); 
3. repositories that host CT data, and
4. registries of repositories such as Re3data (39).
It can be expected that repositories will play an es-
sential role in increasing the accessibility and reus-
ability of research data (2). With due respect to 
other more or less organized ways of data sharing, 
repositories most likely represent the best way for-
ward if we wish to achieve open science. They 
could enable the broad, free re-use of hosted data 
that is citable (persistent identifier) and at the 
same time meeting the acknowledgment need by 
applying the Creative Commons (CC) citation. The 
number of existing repositories is growing expo-
nentially and their features are constantly improv-
ing as can be seen by visiting registries of reposito-
ries. The Re3data registry of repositories started in 
2012 and currently (July 2016) contains basic infor-
mation about more than 1500 repositories. In our 
environmental scan of repositories, we perform 
regular searches of the Re3data looking for even-
tual new repositories that might host CT data, and 
our analysis of relevant repositories starts with Re-
3data. Pharmaceutical company-based reposito-
ries have existed for a while with various levels of 
access. Some joined larger networks of data shar-
ing such as the Welcome Trust coordinated CSDR.
The IMPACT Observatory has been specifically fo-
cusing on publicly accessible repositories of raw 
data and their relevant features. In our environ-
mental scan, we identified heterogeneity in the 
way data are hosted and rather dubious levels of 
curatorship. Repositories exist at various levels, 
from individual institution repositories to interna-
tional ones. They can also be classified according 
to accessibility, from closed to fully open access; 
according to whether the host institution is an ac-
ademic or research institution or the pharmaceuti-
cal industry; and according to data types (whether 
they contain any research data or data from a spe-
cific field). It is important to note that there is no 
domain repository hosting CT data only. 
Discussion
The ultimate goal of opening the CT data is to en-
able secondary analysis which would reduce re-
search waste, speed knowledge creation (i.e. in-
crease the quality and efficiency of trials), increase 
the reliability of evidence, and thus contribute to 
research integrity. All of these outcomes are inter-
connected and regardless of where they start, all 
will be impacted. Although CTs have not reached 
the open data stage, the evolution of CT data shar-
ing is encouraging. Existing data sharing modali-
ties complement each other and can inform fur-
ther transition which relies heavily on the collabo-
ration with the “producer” of the original data.
The learning curve is steep and the rich experi-
ence gained by various ways of ongoing data shar-
ing could inform a development of methods and 
international standards. The IMPACT Observatory 
aims to contribute to the process by assessing the 
dynamics and connecting dots. 
Data sharing starts with good data management, 
which includes the cleaning, preservation, curator-
ship of data at the origin (preferably at the institu-
tional level), anonymization and posting. There is a 
trend to create more repositories with constantly 
improving features, but there is no domain reposi-
tory for clinical trials. Furthermore, we could not 
find any re-analysis of data across repositories and 
believe it would contribute to defining the meth-
odology and data sharing standards. There is a lot 
of discussion about such standards and what they 
should include, but the usable internationally ac-
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cepted standards do not exist. It is not up to repos-
itories to develop them, but rather to the research 
enterprise. Based on what we have learned so far, 
such standards could be built on the accumulated 
expertise, and developed by an interdisciplinary 
and intersectional group. The standards develop-
ment process could be coordinated by the WHO, 
which coordinated a development of the trial reg-
istration standards, or by an international consor-
tium formed specifically for this purpose that 
would include all interested players. 
Currently, data sharing standards are the most im-
portant gap preventing transition to a new level of 
CTs. However, we can start developing such stand-
ards as we have accumulated an impressive 
amount of information and expertise. Also, certain 
necessary elements have been defined such as cit-
ability with persistent identifiers (PIDs; DOIs and 
others) and the increasingly used CC citation, while 
others are being developed. Furthermore, numer-
ous initiatives are contributing to this process such 
as the Declaration of Helsinki, IOM, the All Trials in-
itiative, BioCADDIE/BD2K, CORBEL/ECRIN, and the 
“Vivli” projects. We can also build on the expertise 
of the Research Data Alliance, and coordination 
capacity and authority of the WHO.
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